Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis

In the recently published paper by Xie et al1 in the journal of Drug Design, Development and Therapy, the authors have evaluated interleukin (IL)-17–driven inflammatory responses in 17 cases of human colon adenocarcinomas, 16 cases of human normal colon tissues adjacent to the resected colon adenocarcinomas, ten cases of human ulcerative colitis tissues from biopsies, and eight cases of human benign colon polyps. The authors have observed that human colon adenocarcinomas contained the highest levels of IL-17, which was significantly higher than the IL-17 level in the adenomas, ulcerative colitis, and normal colon tissues (P<0.01). The levels of IL-17 receptor A (IL-17RA) were also the highest in human colon adenocarcinomas, followed by adenomas and ulcerative colitis. The increased level of IL-17 and IL-17RA was accompanied with increased IL-17–driven inflammatory responses, including activation of extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase pathways, increased expression of matrix metalloproteinase (MMP)-9, MMP-7, MMP-2, B-cell lymphoma, and cyclin D1, decreased expression of Bel-2-associated X protein, and increased expression of vascular endothelial growth factor (VEGF) and VEGF receptor expression that were associated with increased angiogenesis.1 These data suggest that IL-17–driven inflammatory responses contribute to the initiation, growth, development, and metastasis of colon cancer. IL-17 and its related signaling pathways may serve as promising novel targets in the development of drugs for the prevention and treatment of colon cancer.

The relationship between IL-17 and tumor growth was first reported in 1999 by Tartour et al2 who showed that IL-17 served as a tumor growth factor in nude mice, although its mechanism remained unclear. Currently, six IL-17 family members have been identified, including IL-17A (namely IL-17), IL-17B (also named IL-20), IL-17C, IL-17D (also named IL-27), IL-17E (also named IL-25), and IL-17F.3 IL-17A binds the receptor complex IL-17RA–IL-17RC to drive inflammatory gene expression. IL-17 is a cytokine produced by Th17 cells, a T helper cell subset developed from an activated CD4+ T cell that is characterized by the expression of intracellular retinoic acid-receptor–related orphan receptor γt and signal transducer and activator of transcription 3 (STAT3). Th17 cells secrete IL-17A, IL-17F, IL-21, and IL-22 to fight extracellular bacteria and fungi by stimulating epithelial cells to produce chemokines and cytokines, which drive the immune response. Other cells, including γδT cells, natural killer (NK) cells, NK T cells, mast cells, and granulocytes can also secrete IL-17. Phosphorylation of STAT3, the downstream signal of IL-6 and IL-21, is a key process in the differentiation of Th17 cells in the presence of transforming growth factor (TGF)-β1.
IL-17 plays an important role in inflammation, immunity, and autoimmunity and has been associated with many immune-related/autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, asthma, allograft rejection, autoimmune hepatitis, and inflammatory bowel disease.\(^1\)\(^-\)\(^7\) IL-17 has proinflammatory effects on a panel of cellular targets, such as epithelium, endothelium, and monocytes/macrophages. IL-17 can stimulate the production of a variety of cytokines such as IL-1β, IL-6, tumor necrosis factor (TNF)-α, and TGF-β, chemokines such as IL-8, and prostaglandins from macrophages, endothelial cells, epithelial cells, and fibroblasts, resulting in and amplifying inflammation.\(^4,6,8\)\(^-\)\(^1\)\(^1\) IL-17–triggered release of IL-6 will consequently activate the STAT3 pathway, which will further activate the nuclear factor (NF)-κB pathway.\(^3\)\(^-\)\(^5\) IL-6 promotes the differentiation of Th17 cells, and IL-17 amplifies IL-6 production in the tumor.

STAT3 is a critical signaling molecule that is involved in the formation of the tumor microenvironment through regulating downstream proinflammatory cytokines and factors promoting tumor growth, progression, and metastasis.\(^8,12\)\(^-\)\(^1\)\(^5\) Constitutively active phosphorylated STAT3 can regulate the differentiation and maturation of Th17 cells to secrete IL-17, which in turn positively feeds back to STAT3 signaling and induces more IL-17 production.\(^8,12\)\(^-\)\(^1\)\(^4\) IL-17 promotes the recruitment and infiltration of myeloid-derived suppressor cells (MDSCs), such as CD11b\(^+\)Gr1\(^+\) cells, to the tumor environment; IL-17 also augments the development and function of MDSCs.\(^4\) Furthermore, IL-17 produced by MDSCs recruits T regulatory cells at tumor sites via upregulation of chemokines CCL17 and CCL22 and enhances their suppressor function via upregulation of CD39 and CD73.\(^4\) MDSCs produce nitric oxide and reactive oxygen species (ROS) and suppress T-cell function through modification of T-cell receptors, inhibition of Janus kinase 3 and STAT5, inhibition of major histocompatibility complex class II expression, and induction of T-cell apoptosis.\(^16\)\(^,\)\(^17\) Meanwhile, IL-17 can enhance the growth of vascular endothelial cells and influence the angiogenic progress by increasing the secretion of cytokines, such as TNF-α, IL-8, and VEGF.\(^4\) IL-17 promotes the invasion of cancer cells via upregulating the expression of MMP-2 and MMP-9 and downregulating the expression of tissue inhibitor of MMP-1 and MMP-2.\(^4\) The increased expression of chemokines by IL-17 attracts neutrophils but not eosinophils.

IL-17 plays a dual role in serving either as a promoter or antitumor factor depending on the type of tumors and the existence of host immune system. In mice, IL-17 promotes an antitumor cytotoxic T-cell and NK-cell response, leading to tumor regression of fibrosarcoma, hematopoietic immunogenic tumor, and lung melanoma; IL-17A has showed a protective effect against chronic lymphocytic leukemia development by promoting immune system–mediated tumor rejection.\(^4,6,9\)\(^,\)\(^1\)\(^0\) Adaptive transfer of Th17 cells reduced tumor growth because Th17 cells developed into Th1 cells in vivo and produced interferon (IFN)-γ and promoted the activation of cytotoxic T lymphocytes.\(^4,6,9\)\(^,\)\(^1\)\(^0\) On the other hand, IL-17 promotes tumorigenesis, proliferation, angiogenesis, and metastasis of many types of tumors.\(^4,6,9\)\(^,\)\(^1\)\(^0\) IL-17−/− mice have been used to determine the endogenous IL-17A functions with regard to tumor progression. One study using B16 melanoma cell lines has showed that IL-17A promoted tumor growth via angiogenesis and induced IL-6 production, which in turn activated oncogenic STAT3, upregulating prosurvival and proangiogenic genes.\(^1\)\(^4\) However, another study using MC38 colon cancer cell lines has showed that IL-17A inhibited tumor growth through antitumor immunity.\(^1\)\(^8\) IL-17 has been detected in various tumors, including breast cancer, gastric cancer, colorectal cancer, cervical cancer, brain tumor, intrahepatic cholangiocarcinoma, and hepatocellular carcinoma.\(^4\) The sources of Th17 cells in cancer may include the trafficking of circulating Th17 cells to tumors and locally induced Th17 cells. The recruitment of Th17 cells is mainly mediated by CCR2-CCL2, CCR4-CCL17/CCL22, and CCR6-CCL20 pathways.\(^4,7\) The Th1 cytokines, such as IFN-γ, and Th2 cytokines, such as IL-4, regulate the differentiation and development of Th17 cells.\(^4,6,9\)\(^,\)\(^1\)\(^0\) The number of Th17 cells gradually increases in the tumor microenvironment during tumor development, and this increase is positively associated with poor prognosis in patients with cancer.\(^4\)

In the 19th century, Dr Rudolf Virchow observed the infiltration of leukocytes in tumor tissues, offering the first indication of a potential link between cancer and inflammation. Up to date, there is enough evidence that inflammation plays a critical role in tumor initiation, growth, and development.\(^1\)\(^9\)\(^-\)\(^2\)\(^3\) A key role for inflammation in carcinogenesis is generally accepted by cancer scientists, and it has become evident that an inflammatory microenvironment is an essential component of all types of tumor. It is known that only a minority of cancers (<10%) are caused by germline mutations, while the vast majority (90%) are ascribed to somatic mutations and environmental factors.\(^2\)\(^0\)\(^,\)\(^2\)\(^2\)–\(^2\)\(^6\) Many cancers are associated with certain forms of chronic inflammation and 15%–20% of cancers are linked to chronic infections.\(^2\)\(^0\)\(^,\)\(^2\)\(^2\)–\(^2\)\(^6\)
It is now well established that the induction of inflammation by bacterial and viral infections increases cancer risk. Chronic *Helicobacter pylori* infection is associated with gastric cancer and mucosa-associated lymphoid tissue lymphoma; *Chlamydia trachomatis* infection increases the risk of cervical cancer; enterotoxigenic *Bacteroides fragilis* infection promotes colon tumorigenesis. Viral infections by high-risk human papillomavirus (HPV) subtypes, such as HPV16 and HPV18, are causal to the development of cervical, anal, and genital cancers. Infections with hepatitis B or C viruses increase the risk of hepatocellular carcinoma; the Epstein–Barr virus can cause lymphomas and nasopharyngeal cancer; human herpes virus 8 (also known as Kaposi sarcoma-associated herpes virus) causes Kaposi sarcoma; HIV infection has been linked to a higher risk of developing Kaposi sarcoma and cervical cancer; human T-lymphotrophic virus-1 has been linked with adult T-cell leukemia/lymphoma; Merkel cell polyomavirus causes Merkel cell carcinoma. Schistosomiasis is associated with the development of bladder cancer; *Opisthorchis viverrini* and *Clonorchis sinensis* infection are linked to increased risk of cholangiocarcinoma. Microorganisms may manipulate and/or collaborate with cellular signaling pathways to promote an inflammatory microenvironment that facilitates cancer development.

Another type of chronic inflammation that precedes tumor development is caused by immune deregulation and autoimmunity. A typical example is inflammatory bowel disease, which significantly increases the risk of colorectal cancer. Chronic inflammation associated with infections or autoimmunity disease precedes carcinogenesis and can contribute to it through induction of oncogenic mutations and activation of oncogenes, inactivation of tumor suppressors, genomic instability, early tumor promotion, and enhanced angiogenesis. Prolonged exposure to environmental irritants (eg, smoking or asbestos) or obesity can also result in low-grade chronic inflammation that precedes tumor development. Particulate materials from tobacco smoke and other environmental irritants can precipitate chronic obstructive pulmonary disease, a condition associated with higher lung cancer risk. The precise mechanisms that underlie the association of obesity with increased risk for tumors, including mammary, renal, esophageal, gastrointestinal and reproductive cancers, remain elusive. The obese setting provides a unique adipose tissue microenvironment with concomitant systemic endocrine alterations favoring both tumor initiation and progression, and considerable metabolic differences are induced by tumor cells in the stromal vascular fraction that surrounds them.

The inflammatory response can promote angiogenesis, oncogene mutation, tumor progression and metastasis, immunosuppression, and genomic instability. Cancer therapy can also trigger an inflammatory response by causing trauma, necrosis, and tissue injury that stimulate tumor reemergence and resistance to therapy. Most solid tumors trigger an intrinsic inflammatory response that builds up a protumorigenic microenvironment. Other tumors, for instance lung cancer, can promote inflammation through active secretion of proinflammatory molecules, such as the extracellular matrix component versican, which activates macrophages through Toll-like receptor 2.

The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy, which facilitates inflammation initiation, development, and amplification. As a result of different forms of inflammation, the tumor microenvironment contains innate immune cells, including macrophages, neutrophils, mast cells, MDSCs, dendritic cells, and NK cells and adaptive immune cells (T and B lymphocytes) in addition to the cancer cells and their surrounding stroma consisting of fibroblasts, endothelial cells, pericytes, and mesenchymal cells. These different types of functional cells communicate with each other by means of direct contact or cytokine and chemokine production and act in autocrine and paracrine manners to shape the tumor environment. The expression of various immune mediators and modulators as well as the abundance and activation state of different cell types in the tumor microenvironment dictate in which direction the balance is tipped and whether tumor-promoting inflammation or antitumor immunity will ensue. In established tumors, this balance is profoundly tilted toward protumor inflammation, since the tumor rarely regresses spontaneously without therapeutic intervention.

The primary immune cells found within the tumor microenvironment are tumor-associated macrophages (TAMs) and T lymphocytes. TAMs promote many important features of tumor progression, including angiogenesis, tumor cell invasion, motility, and intravasation as well as at the metastatic site, stimulation of tumor cell extravasation, and persistent growth. TAMs express an array of effector molecules that inhibit the antitumor immune responses; this includes cell surface receptors, cytokines, chemokines, and enzymes that can suppress CD4+ and CD8+ T-cell effector function directly or indirectly by recruitment of natural regulatory T cells to the tumor microenvironment, as well as by inducing the CD4+ regulatory fraction cells and sustaining their survival. TAMs can also suppress T-cell activity...
by the depletion of L-arginine in the tumor microenvironment. They also modulate therapeutic response and induce multidrug resistance. Mature T cells are divided into two major groups based on the T-cell receptors they produce: αβ and γδ. αβ T cells are further classified into CD8+ cytotoxic T cells and CD4+ Th cells, including Th1, Th2, Th17, and T regulatory cells, as well as NK T cells with four different groups. Similar to TAMs, the tumor-promoting activity of T cells is mediated by cytokines, whereas both cytokines and cytotoxic mechanisms mediate the antitumorigenic function of T lymphocytes. TAMs and T cells in tumors may represent useful therapeutic targets for the development of new interventions.

The cytokines and chemokines produced by various effector cells in the tumor microenvironment play a critical role in tumor initiation and development. Different cytokines can either promote or inhibit tumor development, growth, and metastasis. Several cytokines, such as macrophage migratory inhibitory factor, TNF-α, IL-4, IL-6, IL-10, IL-12, IL-17, IL-23, and TGF-β, have been shown to either promote or inhibit tumor development. Malignant cells or inflammatory cells in the tumor microenvironment can produce TNF-α, and TNF-α signaling can promote cell survival, angiogenesis, progression, and metastasis. Other effects of TNF-α include impairment of immune surveillance through T-cell suppression and inhibition of the cytotoxic activity of activated macrophages. IL-6, a pleiotropic inflammatory cytokine, is considered a key growth factor for both malignant and immune cells. IL-6 acts intrinsically on tumor cells through numerous downstream mediators to support cancer cell proliferation, survival, and metastatic dissemination. IL-6 can also act extrinsically on other cells within the complex tumor microenvironment to sustain a protumor milieu by supporting angiogenesis and tumor evasion of immune surveillance. IL-10 is an immunosuppressive and anti-inflammatory cytokine that is also linked with inflammation-associated cancer. IL-12 is a cytokine that promotes cell-mediated immunity by promoting Th1-type cytokine responses, enhancing the lytic activity of NK/lymphokine-activated killer cells, augmenting specific cytotoxic T-lymphocyte responses, and inducing the production of IFN-γ while it suppresses the development of Th2-type cytokine responses and humoral immunity. IL-23 can activate STAT4 through IL-23 receptors distributed on the membrane of T cells, NK cells, monocytes, and dendritic cells; it is involved in the inflammatory response through promoting MMP-9, enhancing angiogenesis and suppressing CD8+ T-cell infiltration; IL-23 can induce and promote the differentiation of CD4+ naïve T cells to Th17 cells that produce IL-17A, IL-17F, IL-21, and IL-22. TGF-β can inhibit epithelial cell cycle progression and promote apoptosis, contributing to tumor initiation and progression inhibition, but TGF-β also promotes epithelial-to-mesenchymal transition that has been associated with increased tumor cell motility, invasion, and metastasis. Various cytokines can activate downstream effectors such as NF-kB, STAT3/4, and SMADs, therefore controlling the immune and inflammatory milieu to either favor antitumor immunity or enhance tumor progression.

The biochemical mechanisms of how inflammation initiates and promotes tumor development is not fully understood. An inflammatory microenvironment can augment mutation rates and the proliferation of mutated cells. Activated inflammatory cells generate mutagenic ROS, reactive nitrogen intermediates, and other products that can induce marked DNA damage and genomic instability. Inflammatory cells may utilize proinflammatory cytokines such as TNF-α to stimulate ROS accumulation in neighboring epithelial cells. Cytokines offer malignant cells a continuous supply of growth and survival signals in an initially hostile microenvironment. A panel of growth factors and cytokines produced in the tumor microenvironment can confer a stem cell-like phenotype upon tumor progenitors or stimulate stem cell expansion, thereby enlarging the cell pool that is targeted by environmental mutagens. An inflammatory environment also promotes epithelial-to-mesenchymal transition. In most cases, cancer-promoting cytokines act in a paracrine manner, while some cancer cells produce their own cytokines (eg, IL-6).

To date, there is enough evidence indicating that inflammation can influence every step of tumor initiation, development, and progression as well as the response to therapeutic intervention. In the past decade, we have learned a great deal about the complicated mechanisms by which cancer and inflammation interplay, and clearly we should consider inflammation as a new therapeutic target in cancer treatment. Modulation of inflammation may be also a useful approach to reduce cancer risk. Prevention is a much better and more economical way to fight cancer than treating an advanced disease. More studies are warranted to explore how inflammation induces and promotes tumorigenesis and if anti-inflammatory therapies should be integrated into current cancer treatment regimens.

Because IL-17 plays an important role in the initiation and development of cancer, it represents an interesting target in cancer treatment. Anti–IL-17 monoclonal antibodies have
been tested for the treatment of inflammatory autoimmune conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.\textsuperscript{54,55} In January 2015, the US Food and Drug Administration approved the use of secukinumab (trade name Cosentyx\textsuperscript{TM}), an IL-17 inhibiting monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. Ixekizumab (anti–IL-17 monoclonal antibody) and brodalumab (IL-17RA monoclonal antibody) has been shown to be effective in the treatment of patients with moderate-to-severe plaque psoriasis. The anti–IL-12- and IL-23 antibody ustekinumab can also be used to effectively treat psoriasis by reducing IL-17.\textsuperscript{56} There is preliminary evidence from animal studies that inhibition of IL-17 can induce tumor regression.\textsuperscript{4,57} Further studies are certainly needed to explore the role of IL-17 in tumor biology, pathology, diagnosis, and treatment.

**Disclosure**

The authors have no conflicts of interest in this work.

**References**

1. Xie Z, Qu Y, Leng Y, et al. Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. Drug Des Devel Ther. 2015;9:1679–1689.
2. Tartour E, Fossiez F, Joyceu I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenesis of human cervical tumors in nude mice. Cancer Res. 1999;59(15):3698–3704.
3. Iwakura Y, Ishigame H, Sajio S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(3):149–162.
4. Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:627596.
5. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23(7):1069–1075.
6. Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164–174.
7. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010;21(6):413–423.
8. Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in autoimmunity? Front Biosci (Landmark Ed). 2012;17:2306–2326.
9. Maniati E, Soper R, Hagemann T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29(42):5653–5662.
10. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183(7):4169–4175.
11. Dong C. Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev. 2008;226:80–86.
12. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signaling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746.
13. Yu H, Pardoll D. Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.
14. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med. 2009;206(7):1457–1464.
15. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170.
16. Talmadge JE, Gabrilovich DJ. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13(10):739–752.
17. Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol. 2014;41(2):174–184.
18. Kryczek I, Wei S, Szegla W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114(2):357–359.
19. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503.
20. Atsumi T, Singh R, Sabharwal L, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74(1):8–14.
21. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771.
22. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33 Suppl 1:S79–S84.
23. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
24. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
26. Barkwill F, Mantovani A. Inflammation and cancer: back to Vichrov? Lancet. 2001;357(9255):539–545.
27. Silva J, Cerqueira F, Medeiros R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet. 2014;289(4):715–723.
28. Sears CL, Geis AL, Houseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest. 2014;124(10):4166–4172.
29. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.
30. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403–414.
31. Arzumanyan A, Reis HM, Feitelson RA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123–135.
32. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757–768.
33. Mesri EA, Cesurman B, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–719.
34. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer. 2002;2(5):373–382.
35. Qayyum S, Choi JK. Adult T-cell leukemia/lymphoma. Arch Pathol Lab Med. 2014;138(2):282–286.
36. Moens U, Rasheed K, Abdulsalam I, Sveinbjørnsson B. The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmark cancers of cancer. Viruses. 2015;7(4):1871–1901.
37. Rosin MP, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res. 1994;54(7 Suppl):1929s–1933s.
38. Sithithaworn P, Yongvanit P, Duengnai K, Kiatsopit N, Pairojkul C. Herpesvirus. Nat Rev Cancer. 2014;14(10):4166–4172.
39. Decramer M, Janssens W. Chronic obstructive pulmonary disease and implications for HPV status and cervical cancer. Crit Rev Oncol Hematol. 2013;82(2):99–106.
40. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer. 2013;13(4):233–245.
41. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer – mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–465.
42. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.
43. Gorbachev AV, Fairchld RL. Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol. 2014;34(2):103–120.
44. Blonska M, Agarwal NK, Vega F. Shaping of the tumor microenvironment: stromal cells and vessels. *Semin Cancer Biol*. Epub 2015 Mar 18.
45. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity*. 2014;41(1):49–61.
46. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. *Trends Immunol*. 2015;36(4):229–239.
47. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. *Cancer Cell*. 2015;27(4):462–472.
48. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? *Cancer Immunol Immunother*. 2014;63(1):67–72.
49. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. *Semin Immunol*. 2014;26(1):38–47.
50. Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. *Semin Immunol*. 2014;26(1):48–53.
51. Ngiow SF, Teng MW, Smyth MJ. A balance of interleukin-12 and -23 in cancer. *Trends Immunol*. 2013;34(11):548–555.
52. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. *Cytokine Growth Factor Rev*. 2010;21(1):49–59.
53. Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. *Cancer Metastasis Rev*. 2012;31(3–4):553–568.
54. Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. *J Cutan Med Surg*. 2015;19(2):109–114.
55. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. *Rheumatology (Oxford)*. 2015;54(1):20–28.
56. Jacobs A, Rosunbech S. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment. *Clin Exp Dermatol*. 2015.
57. Zarogoulidis P, Katsikogianni F, Tsiodra T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. *Cancer Invest*. 2014;32(5):197–205.